Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

When Pieter van der Meer start­ed rais­ing the cap­i­tal for Gilde Health­care’s fifth fund in the wan­ing months of 2019, he had his eyes on a dif­fer­ent chain of events that could change the health­care sys­tem and per­haps even play to his firm’s ad­van­tage: The US pres­i­den­tial elec­tion.

Since rais­ing their third fund in 2011, the 34-year-old Dutch firm had fo­cused on val­ue-based care. They chose late-stage biotechs that came up with new de­vices and de­liv­ery sys­tems for de-risked es­tab­lished com­pounds, and when they chose pre­clin­i­cal biotechs, they spoke with po­ten­tial phar­ma part­ners, pay­ers and reg­u­la­tors to ask where and at what prices the drug made sense. As the De­mo­c­ra­t­ic pri­ma­ry be­came a con­test over how to low­er health­care costs, it looked like a strat­e­gy that could pay off.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA